Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898192 | 1.00 | ADORA3 (0.50) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL6895644 | 0.89 | ADORA3 (0.65) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL12437840 | 0.86 | ALDH1A1 (0.67) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL6898815 | 0.86 | ALDH1A1 (0.67) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL12116643 | 0.86 | ALDH1A1 (0.67) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL8706499 | 0.85 | ADORA3 (0.53) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL8706504 | 0.85 | ADORA3 (0.53) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL16675426 | 0.84 | ADORA3 (0.73) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL18125928 | 0.84 | ALDH1A1 (0.56) | ADORA3NR1I2PGRPTGS2PDE4D | |
| SCHEMBL10587234 | 0.83 | TSHR (0.41) | ALDH1A1TSHRTDP1MAPTDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-03 | — | — | US | disclosed |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-01-14 | — | — | US | disclosed |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | MORGAN STANLEY SENIOR FUNDING, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LTD (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-07 | — | — | US | disclosed |
| US-8431576-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-04-30 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318869-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | ADORA3 1660/4885NR1I2 2503/4885PGR 4286/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | ADORA3 1660/4885NR1I2 2503/4885PGR 4286/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | ADORA3 198/4885NR1I2 186/4885PGR 1410/4885 |
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | ADORA3 1839/4885NR1I2 593/4885PGR 1841/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | ADORA3 890/4885NR1I2 241/4885PGR 986/4885 |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | ADORA3 1660/4885NR1I2 2503/4885PGR 4286/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | ADORA3 1660/4885NR1I2 2503/4885PGR 4286/4885 |
| US-20150274670-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
| US-20160009713-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | ADORA3 338/4885NR1I2 392/4885PGR 374/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ADORA3 3086/4885NR1I2 277/4885PGR 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.